Biobrás was a pioneer in pharmaceutical biotechnology in Brazil, founded by entrepreneurs who in the 70s invested in the production of biological substances, extracted from plants and animal tissues, intended for the pharmaceutical, food and textile industries.
In the late 1970s, the company entered into a joint venture with one of the world’s leading insulin producers for the local production of animal insulin. We emphasize that already at that time the Company was approved by the FDA (Food and Drug Administration – American body responsible for the control of food and medicines) operating according to Good Manufacturing Practices, which were only implemented in Brazil in 2001, with ANVISA (National Agency of Health Surveillance).
In the 1980s and 1990s, the Company acquired control of the joint venture; developed its recombinant human insulin production technology; and its intellectual property. It also conquered new markets, being one of the few Brazilian companies that exported pharmaceutical products to more than 20 countries in Europe, the Americas and Asia.
In 2001, Biobrás was spun off with the creation of Biomm. The main researchers, the complete know-how of insulin production and other biopharmaceuticals, the patents of the insulin production process and the main business executives were transferred to Biomm.
Biomm dedicated itself exclusively to technological development, licensing of its technology and restructuring to return to the market.
In 2012 the company migrated to the Bovespa+ segment with more transparency in corporate governance and in 2013 it completed the capitalization process for the construction of the factory in Nova Lima, Minas Gerais.
Today, the company works to accelerate the entry into the Brazilian market of biopharmaceuticals and is also looking for other business opportunities in order to offer the market a portfolio of innovative products.
Last update on June 9, 2021